Plain-English translation of NCT05832229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication already used to manage cholesterol, to see if it can help slow liver scarring (fibrosis) in people with cirrhosis. Researchers want to understand whether this medication is safe and effective for your specific liver condition. The study will follow participants for about two years to measure changes in liver stiffness using ultrasound.
Cirrhosis causes the liver to become scarred and stiff, which can lead to serious complications. Current treatments are limited, and doctors are looking for new ways to slow or stop this scarring process. This medication may help protect liver cells and reduce inflammation, but this needs to be tested carefully in people with cirrhosis.
You likely qualify if…
You likely don't qualify if…
You would first take the study medication for 4 weeks openly so doctors can check your safety and how well you take it. Then you would be randomly assigned to either continue the medication or switch to a placebo (inactive pill) for 96 weeks, and neither you nor your doctor would know which you're taking. During this time, you would visit the clinic multiple times for blood tests, ultrasound measurements of your liver stiffness, and check-ups. The study lasts about 2 years total from start to finish.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States